Clinical Trials on Ovarian Mixed Epithelial Carcinoma in New Zealand

Total 2792 results

Hoosier Cancer Research Network
University of Sydney; Bionomics Limited; Australia New Zealand Gynaecological...

Withdrawn

BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

Ovarian Cancer

United States, Australia, New Zealand
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

Neutropenia | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Ovarian Carcinosarcoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer | Infectious Disorder

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States
Splash Pharmaceuticals, Inc.

Unknown

Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer

Ovarian Epithelial Cancer

United States
Nuvectis Pharma, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Recruiting

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Ovarian Cancer | Ovarian Endometrioid Adenocarcinoma | Advanced Solid Tumor | Ovarian Clear Cell Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Clear Cell Tumor | Ovarian Endometrioid Tumor | ARID1A Gene Mutation

United States, United Kingdom
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States, Japan
New Mexico Cancer Care Alliance
Celgene Corporation

Terminated

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer | Epithelial Ovarian Cancer | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
NYU Langone Health

Completed

Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma

Ovarian Neoplasms

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Primary Peritoneal Cavity Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Mixed Epithelial Carcinoma | Ovarian...

United States
Odense University Hospital
Zealand University Hospital; Rigshospitalet, Denmark; Herlev Hospital

Recruiting

FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian Cancer (FRAGINOC)

Ovarian Cancer | Frailty

Denmark
Auckland District Health Board
Novartis; University of Auckland, New Zealand; IGENZ, Ltd., Auckland

Unknown

1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC (DILIGENCE-1)

Clear Cell Renal Cell Carcinoma

New Zealand
National Cancer Institute (NCI)

Terminated

Oxaliplatin and Topotecan in Advance Ovarian Cancer

Recurrent Ovarian Epithelial Cancer

United States
Morphotek

Completed

Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer

Epithelial Ovarian Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma | Fallopian Tube... and other conditions

United States
AbbVie (prior sponsor, Abbott)

Completed

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Ovarian Cancer

United States, Australia, Canada, Hungary, Israel, New Zealand, Poland, United Kingdom
All India Institute of Medical Sciences, New Delhi

Unknown

Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study

Ovarian Carcinoma

India
Memorial Sloan Kettering Cancer Center

Completed

Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

United States
Provectus Pharmaceuticals

Completed

PV-10 Chemoablation of Recurrent Breast Carcinoma

Breast Cancer

New Zealand
University College, London

Recruiting

Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients (ICON9)

Ovarian Cancer

Australia, United Kingdom, Canada, New Zealand
Roswell Park Cancer Institute

Completed

Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer

Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditions

United States
ABK Biomedical

Completed

Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRC

Metastatic Colorectal Cancer | Liver Cancer | Hepatocellular Carcinoma Non-resectable

New Zealand
New Mexico Cancer Care Alliance
Genentech, Inc.; NYU Langone Health

Completed

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

Ovarian Cancer

United States
Icahn School of Medicine at Mount Sinai

Withdrawn

To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Ovarian Neoplasms

United States
NYU Langone Health
Genentech, Inc.; University of New Mexico Cancer Center

Completed

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Ovarian Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Gastrointestinal Complication and other conditions

United States
Montefiore Medical Center
National Cancer Institute (NCI)

Completed

Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Ovarian Cancer | Peritoneal Cavity Cancer

United States
NYU Langone Health
GlaxoSmithKline

Withdrawn

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

Ovarian Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Queens Cancer Center of Queens Hospital

Completed

Women Surviving Ovarian Cancer

Quality of Life | Epithelial Ovarian Cancer | Survivorship

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

Ovarian Cancer

United States
Sanofi

Completed

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Advanced Epithelial Ovarian Cancer

United States
Garden State Cancer Center at the Center for Molecular...
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer

Ovarian Cancer

United States
Far Eastern Memorial Hospital

Completed

Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer

Advanced Ovarian Cancer

Taiwan
Cascadian Therapeutics Inc.
Celldex Therapeutics

Completed

Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer

Advanced Breast Carcinoma | Advanced Ovarian Carcinoma

United States
NYU Langone Health

Completed

Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer

Ovarian Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study

Ovarian Cancer

United States
Weill Medical College of Cornell University

Terminated

Weekly Topotecan Therapy in Patients With Ovarian Cancer

Ovarian Cancer

United States
NYU Langone Health
OSI Pharmaceuticals

Terminated

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

Ovarian Cancer

United States
NYU Langone Health

Terminated

NYU Ovarian Cancer Early Detection Program Blood and Genetics

Ovarian Cancer

United States
Morphotek

Completed

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Epithelial Ovarian Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.

Ovarian Cancer

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; Marker Therapeutics, Inc.

Completed

TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer

United States
Memorial Sloan Kettering Cancer Center
Johns Hopkins University; M.D. Anderson Cancer Center

Completed

A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer

Ovarian Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics

Ovarian Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Undifferentiated Adenocarcinoma

United States
NanOlogy, LLC
US Biotest, Inc.

Terminated

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

Ovarian Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Ovarian Carcinoma

United States, Israel
Memorial Sloan Kettering Cancer Center

Terminated

Sexual Functioning After Primary Treatment of Ovarian Cancer

Ovarian Cancer | Sexual Dysfunction

United States

Clinical Trials on Ovarian Mixed Epithelial Carcinoma in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations